Spots Global Cancer Trial Database for metastatic squamous neck cancer with occult primary squamous cell carcinoma

Every month we try and update this database with for metastatic squamous neck cancer with occult primary squamous cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00639769	Head and Neck C...	cisplatin irinotecan hydr...	18 Years -	Vanderbilt-Ingram Cancer Center
Biomarkers in Patients With Head and Neck Cancer	NCT01466257	Head and Neck C...	cetuximab cisplatin DNA analysis gene expression... mutation analys... laboratory biom...	18 Years - 120 Years	Eastern Cooperative Oncology Group
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer	NCT00040807	Head and Neck C...	docetaxel irinotecan hydr...	18 Years - 120 Years	Eastern Cooperative Oncology Group
Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy	NCT00004865	Head and Neck C...	cetuximab cisplatin fluorouracil paclitaxel	18 Years -	National Cancer Institute (NCI)
Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer	NCT00006107	Head and Neck C...	Taxotere Surgery radiation thera...	18 Years -	Dana-Farber Cancer Institute
Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer	NCT00023959	Metastatic Squa... Recurrent Adeno... Recurrent Basal... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage III Adeno... Stage III Basal... Stage III Esthe... Stage III Inver... Stage III Lymph... Stage III Lymph... Stage III Midli... Stage III Mucoe... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Adenoi... Stage IV Basal ... Stage IV Esthes... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Untreated Metas...	hydroxyurea fluorouracil bevacizumab radiation thera... filgrastim laboratory biom...	18 Years -	National Cancer Institute (NCI)
Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00020189	Head and Neck C... Thromboembolism	acetylsalicylic... alvocidib clopidogrel bis...	18 Years -	National Cancer Institute (NCI)
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00507767	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	dasatinib pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer	NCT00482872	Head and Neck C...	gene expression... mutation analys... polymerase chai... polymorphism an... flow cytometry laboratory biom...	18 Years - 120 Years	Vanderbilt University Medical Center
S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00096512	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer Untreated Metas...	sorafenib tosyl... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Oxaliplatin in Treating Patients With Advanced Head and Neck Cancer	NCT00005035	Head and Neck C...	oxaliplatin	18 Years -	National Cancer Institute (NCI)
DNA Analysis of Tissue Samples From Patients With Head and Neck Cancer	NCT00898664	Head and Neck C...	cytogenetic ana... gene expression... mutation analys... polymerase chai... immunohistochem... laboratory biom...	18 Years -	Vanderbilt-Ingram Cancer Center
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	NCT02035527	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Oral ... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer Untreated Metas...	sorafenib tosyl... cisplatin docetaxel Correlative Stu...	18 Years -	Ohio State University Comprehensive Cancer Center
Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery	NCT00041171	Adult Solid Tum... Breast Cancer Head and Neck C... Kidney and Urin... Male Reproducti... Thorax and Resp...	Hypericum perfo... docetaxel placebo	18 Years - 120 Years	Alliance for Clinical Trials in Oncology
Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer	NCT00897793	Breast Cancer Colorectal Canc... Head and Neck C... Lung Cancer Prostate Cancer	venipuncture radiation thera...	18 Years -	Vanderbilt-Ingram Cancer Center
Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer	NCT00281866	Head and Neck C...	erlotinib hydro...	18 Years - 120 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer	NCT00898742	Head and Neck C...	DNA and tissue ... reverse transcr... mass spectromet...	-	Vanderbilt-Ingram Cancer Center
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	NCT00337129	Head and Neck C...	eribulin mesyla...	18 Years -	National Cancer Institute (NCI)
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00507767	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	dasatinib pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy	NCT00898430	Head and Neck C...	DNA Microarray ... MALDI-TOF mass ... DNA microarray ...	-	Vanderbilt-Ingram Cancer Center
Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer	NCT00896675	Head and Neck C...	proteomic profi... proteomic profi...	-	Vanderbilt-Ingram Cancer Center
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck	NCT00720304	Head and Neck C...	docetaxel erlotinib hydro... fluorescence in... polymerase chai... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... therapeutic con... intensity-modul... radiation thera...	18 Years -	Case Comprehensive Cancer Center
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors	NCT00526149	Breast Cancer Endometrial Can... Head and Neck C... Melanoma (Skin) Ovarian Cancer Sarcoma	BI 2536 high performanc... mass spectromet... pharmacological...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00639769	Head and Neck C...	cisplatin irinotecan hydr...	18 Years -	Vanderbilt-Ingram Cancer Center
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy	NCT01156142	Head and Neck C... Mucositis Oral Complicati... Pain	doxepin hydroch... placebo	18 Years -	Alliance for Clinical Trials in Oncology
Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer	NCT01313390	Head and Neck C...	docetaxel everolimus laboratory biom... pharmacological...	18 Years -	University College, London
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.	NCT01469429	Metastatic Squa... Salivary Gland ... Stage 0 Hypopha... Stage 0 Larynge... Stage 0 Lip and... Stage 0 Nasopha... Stage 0 Orophar... Stage 0 Paranas... Stage I Salivar... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Verruco... Stage I Verruco... Stage II Saliva... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Verruc... Stage II Verruc... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Oral ... Stage IVA Squam... Stage IVA Nasal... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Oral ... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Oral ... Stage IVC Squam... Paranasal Sinus... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	placebo laboratory biom... questionnaire a... chemoprevention chemoprevention placebo	21 Years -	Ohio State University Comprehensive Cancer Center
SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes	NCT02644122	Metastatic Squa...	SF1126	18 Years -	University of California, San Diego
Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer	NCT00049283	Metastatic Squa... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Squamo... Stage IV Squamo... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer Untreated Metas...	erlotinib hydro... docetaxel radiation thera... therapeutic con... laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer	NCT00482872	Head and Neck C...	gene expression... mutation analys... polymerase chai... polymorphism an... flow cytometry laboratory biom...	18 Years - 120 Years	Vanderbilt University Medical Center
Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer	NCT00049283	Metastatic Squa... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Squamo... Stage IV Squamo... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer Untreated Metas...	erlotinib hydro... docetaxel radiation thera... therapeutic con... laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab	NCT00939627	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer Untreated Metas...	cetuximab placebo sorafenib tosyl... laboratory biom... quality-of-life...	18 Years -	National Cancer Institute (NCI)
Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer	NCT00896675	Head and Neck C...	proteomic profi... proteomic profi...	-	Vanderbilt-Ingram Cancer Center
Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer	NCT02245100	Metastatic Squa... Salivary Gland ... Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-sm... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer Untreated Metas...	Cytology specim... Laboratory biom...	18 Years -	Thomas Jefferson University
Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck	NCT00906360	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Tongue Cancer Untreated Metas...	sunitinib malat... pharmacological... 3-dimensional c... cetuximab	18 Years -	National Cancer Institute (NCI)
Arginine/Omega-3 Fatty Acids/Nucleotides Nutritional Supplement in Treating Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy	NCT00559156	Head and Neck C...	arginine/omega-... cisplatin adjuvant therap... radiation thera...	18 Years -	National Cancer Institute (NCI)
Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer	NCT00248560	Head and Neck C...	docetaxel Gemcitabine	18 Years - 120 Years	Barbara Ann Karmanos Cancer Institute
Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer	NCT00448552	Head and Neck C...	capecitabine oxaliplatin	18 Years - 120 Years	University of Miami
Immunotoxin Therapy in Treating Patients With Advanced Cancer	NCT00006981	Cervical Cancer Fallopian Tube ... Head and Neck C... Lung Cancer Malignant Mesot... Ovarian Cancer Pancreatic Canc... Primary Periton...	SS1(dsFv)-PE38 ...	18 Years -	National Cancer Institute (NCI)
Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer	NCT00573989	Head and Neck C...	erlotinib hydro... pemetrexed diso... quality-of-life... intensity-modul...	18 Years - 120 Years	Wake Forest University Health Sciences
Insomnia in Patients Undergoing Chemotherapy and Radiation Therapy for Head and Neck Cancer	NCT00616590	Fatigue Head and Neck C... Psychosocial Ef... Sleep Disorders	medical chart r... questionnaire a... fatigue assessm... quality-of-life...	21 Years -	Vanderbilt University
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors	NCT00526149	Breast Cancer Endometrial Can... Head and Neck C... Melanoma (Skin) Ovarian Cancer Sarcoma	BI 2536 high performanc... mass spectromet... pharmacological...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer	NCT00017511	Head and Neck C... Oral Complicati... Radiation Toxic...	cevimeline hydr...	18 Years -	Daiichi Sankyo
Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer	NCT01313390	Head and Neck C...	docetaxel everolimus laboratory biom... pharmacological...	18 Years -	University College, London
Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer	NCT00022594	Head and Neck C...	liposomal lurto...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Family Quality of Life Among Families With a Member Who is a Cancer Patient	NCT00544336	Breast Cancer Colorectal Canc... Head and Neck C... Lung Cancer Prostate Cancer Solid Tumor	questionnaire a... survey administ... quality-of-life...	21 Years -	Vanderbilt-Ingram Cancer Center
Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer	NCT00090337	Head and Neck C... Pain	acupuncture the... standard follow...	-	Memorial Sloan Kettering Cancer Center
Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer	NCT00896675	Head and Neck C...	proteomic profi... proteomic profi...	-	Vanderbilt-Ingram Cancer Center
Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer	NCT00573989	Head and Neck C...	erlotinib hydro... pemetrexed diso... quality-of-life... intensity-modul...	18 Years - 120 Years	Wake Forest University Health Sciences
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor	NCT01096381	Breast Cancer Cardiovascular ... Colorectal Canc... Fallopian Tube ... Head and Neck C... Lung Cancer Ovarian Cancer Peritoneal Cavi... Unspecified Adu...	laboratory biom... questionnaire a...	18 Years -	Vanderbilt-Ingram Cancer Center
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor	NCT01096381	Breast Cancer Cardiovascular ... Colorectal Canc... Fallopian Tube ... Head and Neck C... Lung Cancer Ovarian Cancer Peritoneal Cavi... Unspecified Adu...	laboratory biom... questionnaire a...	18 Years -	Vanderbilt-Ingram Cancer Center
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00507767	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	dasatinib pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer	NCT00004070	Head and Neck C...	IL-12	18 Years -	Dana-Farber Cancer Institute
Immunotoxin Therapy in Treating Patients With Advanced Cancer	NCT00006981	Cervical Cancer Fallopian Tube ... Head and Neck C... Lung Cancer Malignant Mesot... Ovarian Cancer Pancreatic Canc... Primary Periton...	SS1(dsFv)-PE38 ...	18 Years -	National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients With Head and Neck Cancer	NCT00404339	Head and Neck C...	mutant p53 pept... tetanus toxoid ... adjuvant therap...	18 Years - 120 Years	University of Pittsburgh
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck	NCT00033618	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	ixabepilone laboratory biom...	18 Years -	National Cancer Institute (NCI)
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck	NCT00720304	Head and Neck C...	docetaxel erlotinib hydro... fluorescence in... polymerase chai... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... therapeutic con... intensity-modul... radiation thera...	18 Years -	Case Comprehensive Cancer Center
Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00006471	Head and Neck C...	Fenretinide	18 Years -	M.D. Anderson Cancer Center
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.	NCT01469429	Metastatic Squa... Salivary Gland ... Stage 0 Hypopha... Stage 0 Larynge... Stage 0 Lip and... Stage 0 Nasopha... Stage 0 Orophar... Stage 0 Paranas... Stage I Salivar... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Verruco... Stage I Verruco... Stage II Saliva... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Verruc... Stage II Verruc... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Oral ... Stage IVA Squam... Stage IVA Nasal... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Oral ... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Oral ... Stage IVC Squam... Paranasal Sinus... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	placebo laboratory biom... questionnaire a... chemoprevention chemoprevention placebo	21 Years -	Ohio State University Comprehensive Cancer Center
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck	NCT00720304	Head and Neck C...	docetaxel erlotinib hydro... fluorescence in... polymerase chai... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... therapeutic con... intensity-modul... radiation thera...	18 Years -	Case Comprehensive Cancer Center
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy	NCT01806675	Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Male Breast Can... Metastatic Squa... Recurrent Adeno... Recurrent Adult... Recurrent Basal... Recurrent Colon... Recurrent Esthe... Recurrent Hypop... Recurrent Inver... Recurrent Laryn... Recurrent Lip a... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Nasop... Recurrent Non-s... Recurrent Oroph... Recurrent Pancr... Recurrent Paran... Recurrent Recta... Recurrent Renal... Recurrent Saliv... Stage IIIA Brea... Stage IIIA Non-... Stage IIIB Brea... Stage IIIB Non-... Stage IIIC Brea... Stage IV Breast... Stage IV Non-sm... Stage IV Pancre... Stage IV Renal ... Stage IVA Colon... Stage IVA Recta... Stage IVA Saliv... Stage IVB Colon... Stage IVB Saliv... Stage IVC Saliv... Tongue Cancer Unspecified Adu...	18F-fludeoxyglu... 18F-FPPRGD2	18 Years -	Stanford University
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer	NCT01316757	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Tongue Cancer Untreated Metas...	cetuximab paclitaxel carboplatin erlotinib hydro... laboratory biom...	18 Years -	Fox Chase Cancer Center
Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397	NCT01466244	Head and Neck C...	cetuximab cisplatin gene expression... microarray anal... immunohistochem... laboratory biom...	18 Years - 120 Years	Eastern Cooperative Oncology Group
SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes	NCT02644122	Metastatic Squa...	SF1126	18 Years -	University of California, San Diego
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck	NCT00720304	Head and Neck C...	docetaxel erlotinib hydro... fluorescence in... polymerase chai... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... therapeutic con... intensity-modul... radiation thera...	18 Years -	Case Comprehensive Cancer Center
Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer	NCT00004070	Head and Neck C...	IL-12	18 Years -	Dana-Farber Cancer Institute
Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer	NCT00090337	Head and Neck C... Pain	acupuncture the... standard follow...	-	Memorial Sloan Kettering Cancer Center
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	NCT00337129	Head and Neck C...	eribulin mesyla...	18 Years -	National Cancer Institute (NCI)
Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer	NCT00024089	Head and Neck C...	gefitinib	18 Years -	National Cancer Institute (NCI)
Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer	NCT00387335	Metastatic Squa... Recurrent Metas... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo...	sunitinib malat...	18 Years -	National Cancer Institute (NCI)
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00095628	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Stage IVA Saliv... Stage IVA Squam... Stage IVB Saliv... Stage IVB Squam... Stage IVC Saliv... Stage IVC Squam...	ispinesib laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients With Head and Neck Cancer	NCT00404339	Head and Neck C...	mutant p53 pept... tetanus toxoid ... adjuvant therap...	18 Years - 120 Years	University of Pittsburgh
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck	NCT00005647	Head and Neck C...	paclitaxel semaxanib	18 Years -	Case Comprehensive Cancer Center
Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer	NCT00006799	Anorexia Cachexia Head and Neck C... Quality of Life	megestrol aceta... quality-of-life...	18 Years - 120 Years	Wake Forest University Health Sciences
Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer	NCT00387335	Metastatic Squa... Recurrent Metas... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo...	sunitinib malat...	18 Years -	National Cancer Institute (NCI)
Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00020189	Head and Neck C... Thromboembolism	acetylsalicylic... alvocidib clopidogrel bis...	18 Years -	National Cancer Institute (NCI)
TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck	NCT01334177	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Saliva... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	TLR8 agonist VT... cetuximab laboratory biom... pharmacogenomic...	18 Years -	University of Washington
Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants	NCT00898638	Head and Neck C...	biologic sample... medical chart r...	18 Years -	Vanderbilt University Medical Center
Randomized Amifostine For SCCHN	NCT00095927	Chemotherapeuti... Head and Neck C... Mucositis Radiation Toxic... Xerostomia	Amifostine Carboplatin Paclitaxel radiation	18 Years -	Dana-Farber Cancer Institute
Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer	NCT00003264	Head and Neck C...	cisplatin gemcitabine hyd...	18 Years -	Fox Chase Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: